Leukemia that was observed in a small number of mitoxantrone treated multiple sclerosis patients may be the result of patients' genetic makeup, Italian researchers said.
Variations in genes involved with DNA repair processes and in the gene encoding the CYP3A4 drug-metabolizing enzyme were significantly associated with secondary acute promyelocytic leukemia (sAPL) in a case-control study, according to Francesco Lo-Coco, MD, of Tor Vergata University in Rome, and colleagues online in Neurology.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1347